1. Home
  2. ALT vs FERA Comparison

ALT vs FERA Comparison

Compare ALT & FERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • FERA
  • Stock Information
  • Founded
  • ALT 1997
  • FERA 2024
  • Country
  • ALT United States
  • FERA Cayman Islands
  • Employees
  • ALT N/A
  • FERA N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • FERA
  • Sector
  • ALT Health Care
  • FERA
  • Exchange
  • ALT Nasdaq
  • FERA Nasdaq
  • Market Cap
  • ALT 292.0M
  • FERA 317.4M
  • IPO Year
  • ALT N/A
  • FERA 2025
  • Fundamental
  • Price
  • ALT $3.67
  • FERA $10.15
  • Analyst Decision
  • ALT Strong Buy
  • FERA
  • Analyst Count
  • ALT 6
  • FERA 0
  • Target Price
  • ALT $17.40
  • FERA N/A
  • AVG Volume (30 Days)
  • ALT 2.8M
  • FERA 3.0
  • Earning Date
  • ALT 08-12-2025
  • FERA 01-01-0001
  • Dividend Yield
  • ALT N/A
  • FERA N/A
  • EPS Growth
  • ALT N/A
  • FERA N/A
  • EPS
  • ALT N/A
  • FERA N/A
  • Revenue
  • ALT $20,000.00
  • FERA N/A
  • Revenue This Year
  • ALT N/A
  • FERA N/A
  • Revenue Next Year
  • ALT $761,880.20
  • FERA N/A
  • P/E Ratio
  • ALT N/A
  • FERA N/A
  • Revenue Growth
  • ALT N/A
  • FERA N/A
  • 52 Week Low
  • ALT $2.90
  • FERA $10.00
  • 52 Week High
  • ALT $11.16
  • FERA $10.60
  • Technical
  • Relative Strength Index (RSI)
  • ALT 46.45
  • FERA N/A
  • Support Level
  • ALT $3.35
  • FERA N/A
  • Resistance Level
  • ALT $3.66
  • FERA N/A
  • Average True Range (ATR)
  • ALT 0.18
  • FERA 0.00
  • MACD
  • ALT 0.05
  • FERA 0.00
  • Stochastic Oscillator
  • ALT 58.57
  • FERA 0.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About FERA Fifth Era Acquisition Corp I Class A Ordinary Shares

Fifth Era Acquisition Corp I is a blank check company.

Share on Social Networks: